Insulin is lifesaving for people with diabetes and is included on the Model List of Essential Medicines formulated by the World Health Organization.1 This means it should be available at all times at a price the individual and the community can afford.1 However, over the past decade, insulin prices have tripled in the United States, while out-of-pocket costs per prescription doubled.2,3 High costs of medications can contribute to nonadherence,4 but the prevalence of cost-related insulin underuse is unknown.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Herkert D, Vijayakumar P, Luo J, et al. Cost-Related Insulin Underuse Among Patients With Diabetes. JAMA Intern Med. Published online December 03, 2018. doi:10.1001/jamainternmed.2018.5008
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: